ALK and non-small cell lung carcinoma: Of note, in the ALNEO Trial, patients with potentially resectable stage III ALK-positive NSCLC (any T with N2, T4N0-1) were randomized to receive oral alectinib 600 mg twice daily for two cycles of 4 weeks each (8 weeks in total) during the neoadjuvant phase, followed by adjuvant alectinib for 24 cycles (96 weeks) after radical surgery [64].